The story of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial release generated substantial profits, the expiration of its intellectual property protection opened the https://bookmarkingalpha.com/story21641266/sildenafil-and-the-pharmaceutical-industry-a-volatile-bet